• Predicting Major Bleeding Risk in Extended VTE Anticoagulati

  2026-06-04

  This study introduces and validates the CHAP model, a streamlined clinical tool for predicting major bleeding during extended anticoagulation in patients with unprovoked or weakly provoked venous thromboembolism (VTE). By comparing CHAP with established bleeding risk scores, the research informs safer long-term anticoagulation decisions.

• (S)-(+)-Ibuprofen: Precision COX Inhibitor Workflows & Troub

  2026-06-04

  (S)-(+)-Ibuprofen sets the benchmark for selective COX inhibition, enabling reproducible results in inflammation and pain mechanism research. This guide details optimized protocols, advanced use-cases, and troubleshooting insights—empowering researchers to maximize assay reliability using APExBIO’s high-purity reagent.

• Syringin Targets EGFR/PI3K/Akt to Sensitize RCC to Sunitinib

  2026-06-03

  The referenced study identifies Syringin as a bioactive natural product that inhibits renal cell carcinoma (RCC) cell growth and enhances sunitinib efficacy by modulating the EGFR/PI3K/Akt pathway. These findings highlight a mechanistically validated strategy to overcome drug resistance in RCC using natural product-based interventions.

• N6-Methyl-dATP: Advancing Leukemia Genomics and Epigenetic F

  2026-06-03

  Explore how N6-Methyl-dATP enables precise interrogation of DNA replication fidelity and epigenetic regulation in leukemia genomics. This article delivers fresh insights into protocol design and translational impact, grounded in cutting-edge research.

• Cy5 NHS ester(Et): Technical Guide for Protein Labeling Work

  2026-06-02

  Cy5 NHS ester(Et) is a water-soluble fluorescent dye optimized for covalent labeling of amino groups in proteins and other biomolecules, addressing the need for reliable, high-purity tagging in detection assays such as immunofluorescence staining, flow cytometry, and fluorescence microscopy. It should not be used in ethanol-based workflows or for protocols requiring long-term storage of labeling solutions. Prompt, protocol-driven use ensures reproducible results in research applications.

• ISRIB (trans-isomer): Advanced PERK Inhibitor for ER Stress

  2026-06-02

  ISRIB (trans-isomer) from APExBIO is redefining how researchers probe the integrated stress response, offering unmatched precision for ER stress, apoptosis, and fibrotic disease models. Its robust potency and mechanistic selectivity empower both fundamental and translational breakthroughs, especially in liver fibrosis and cognitive research.

• Sulfaphenazole: CYP2C9 Inhibitor for Vascular and Antibacter

  2026-06-01

  Sulfaphenazole is a selective CYP2C9 inhibitor with robust evidence for modulating vascular endothelial function and inhibiting bacterial folate synthesis. Its pharmacological profile includes potent enzyme inhibition and low cytotoxicity, supporting its use in translational research. APExBIO’s Sulfaphenazole (C4131) is validated for vascular dysfunction and antibacterial assays.

• Afatinib (BIBW 2992): Irreversible ErbB Inhibition in Person

  2026-06-01

  Explore how Afatinib, an irreversible ErbB family tyrosine kinase inhibitor, transforms targeted therapy research by enabling precise EGFR, HER2, and HER4 pathway inhibition in patient-derived assembloid models. This article uniquely dissects Afatinib’s mechanistic advantages and practical considerations for translational cancer biology.

• Topotecan’s Mechanism and Clinical Impact: Insights for Topo

  2026-05-31

  The referenced review details the pharmacology and clinical performance of topotecan, a water-soluble topoisomerase I inhibitor, emphasizing its unique mechanism, pharmacokinetics, and efficacy in several solid tumors. These insights directly inform the design and interpretation of DNA damage and apoptosis assays, especially when compared to established topoisomerase II inhibitors like Etoposide (VP-16), enabling researchers to optimize cancer chemotherapy research strategies.

• EZ Cap™ Firefly Luciferase mRNA: Precision Tools for Biolumi

  2026-05-30

  EZ Cap™ Firefly Luciferase mRNA delivers robust, sustained bioluminescence for gene regulation, translation efficiency, and in vivo imaging. Through its Cap 1 structure and optimized poly(A) tail, it addresses the need for reliable, high-fidelity reporter expression in advanced mRNA delivery workflows.

• Thioguanine in Cancer and Antiviral Workflows: Protocols & P

  2026-05-29

  Thioguanine (6-thioguanine) stands apart as a dual-action tool for researchers targeting cancer cell proliferation and viral inhibition, with unique epigenetic mechanisms validated by recent transcriptomics. This guide delivers stepwise protocols, data-driven troubleshooting, and cutting-edge insights for maximizing Thioguanine’s translational impact in oncology and virology.

• DAPI Solution (1 mg/mL): Applied Workflows for Nuclear Visua

  2026-05-29

  Unlock robust, reproducible nuclear staining and apoptosis detection with DAPI Solution (1 mg/mL) from APExBIO. This guide delivers actionable protocols, advanced troubleshooting, and translational insights for flow cytometry and fluorescence microscopy, drawing on recent breakthroughs in tumor and cell death research.

• Erlotinib (NSC 718781): Applied EGFR Inhibition in Oncology

  2026-05-28

  Erlotinib enables precision dissection of EGFR-driven oncogenic signaling, especially in complex tumor models involving SCUBE3-mediated resistance and immune evasion. This guide delivers actionable workflows, troubleshooting strategies, and data-driven insights for leveraging Erlotinib in translational cancer research.

• DiscoveryProbe FDA-approved Drug Library in Cancer Screening

  2026-05-28

  Accelerate drug repositioning and target identification with the DiscoveryProbe FDA-approved Drug Library. This robust platform streamlines high-throughput and high-content screening workflows, offering researchers unparalleled access to clinically validated compounds for advanced cancer and neurodegenerative disease studies.

• Gramine as a Precision Ferroptosis Inducer in Cancer Researc

  2026-05-27

  Gramine (1-(1H-indol-3-yl)-N,N-dimethylmethanamine) transforms triple-negative breast cancer research by enabling targeted interrogation of ferroptosis via the CUL3–MTDH axis. APExBIO’s high-purity Gramine empowers reproducible workflows and advanced applications in cancer biology.

454 records 16/31 page Previous Next First page 上5页 1617181920 下5页 Last page